Baxter International (BAX)
(Delayed Data from NYSE)
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $36.92 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $36.92 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Zacks News
New Strong Buy Stocks for January 18th
by Zacks Equity Research
KBH, BAX, F, EGO, and AXS have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
PacBio (PACB) to Leverage Google's Deep Learning Technologies
by Zacks Equity Research
PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Neogen's (NEOG) better-than-expected Q2 revenues and robust growth across Food Safety & Animal Safety businesses instill investor confidence.
Best Momentum Stocks to Buy for January 18th
by Zacks Equity Research
BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022
Best Income Stocks to Buy for January 18th
by Zacks Equity Research
BAX, F, and WBS made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 18, 2022
5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market
by Nalak Das
We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.
Cardiovascular Systems (CSII) Expands Lithotripsy Technology
by Zacks Equity Research
Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.
New Strong Buy Stocks for January 17th
by Zacks Equity Research
AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
by Riya Anand
Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
Baxter's (BAX) $100M Investment to Strengthen Global Presence
by Zacks Equity Research
Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Baxter International (BAX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
Baxter International (BAX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
by Zacks Equity Research
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How
by Zacks Equity Research
Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.